Eva Hambruch

794 total citations
19 papers, 654 citations indexed

About

Eva Hambruch is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, Eva Hambruch has authored 19 papers receiving a total of 654 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 9 papers in Epidemiology and 6 papers in Molecular Biology. Recurrent topics in Eva Hambruch's work include Drug Transport and Resistance Mechanisms (9 papers), Liver Disease Diagnosis and Treatment (8 papers) and Peroxisome Proliferator-Activated Receptors (5 papers). Eva Hambruch is often cited by papers focused on Drug Transport and Resistance Mechanisms (9 papers), Liver Disease Diagnosis and Treatment (8 papers) and Peroxisome Proliferator-Activated Receptors (5 papers). Eva Hambruch collaborates with scholars based in Germany, Austria and United States. Eva Hambruch's co-authors include Claus Kremoser, Olaf Kinzel, Michael Burnet, Wolfgang Schliebs, Ulrich Deuschle, Ralf Erdmann, Christian Gege, Sanja Perović‐Ottstadt, Nina Hambruch and Thomas Schlüter and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Journal of Hepatology.

In The Last Decade

Eva Hambruch

19 papers receiving 635 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva Hambruch Germany 11 311 275 249 217 162 19 654
Cristina Di Giorgio Italy 16 206 0.7× 221 0.8× 286 1.1× 133 0.6× 154 1.0× 36 648
Michaela Mueller Austria 6 310 1.0× 148 0.5× 160 0.6× 110 0.5× 139 0.9× 9 507
Justin D. Schumacher United States 9 227 0.7× 169 0.6× 124 0.5× 106 0.5× 90 0.6× 10 415
Dina Hazem Ziada Egypt 14 298 1.0× 317 1.2× 89 0.4× 218 1.0× 81 0.5× 32 684
Vittoria Massafra Netherlands 9 155 0.5× 182 0.7× 214 0.9× 68 0.3× 131 0.8× 9 425
Florence Y. Lee United States 7 163 0.5× 221 0.8× 384 1.5× 61 0.3× 247 1.5× 8 616
Kangkang Yu China 16 255 0.8× 331 1.2× 84 0.3× 161 0.7× 66 0.4× 44 708
Asato Tachibana Japan 8 200 0.6× 207 0.8× 130 0.5× 292 1.3× 145 0.9× 8 647
Mariska Geuken Netherlands 11 207 0.7× 214 0.8× 564 2.3× 137 0.6× 303 1.9× 14 806
Yi-Ping Rao United States 11 106 0.3× 237 0.9× 337 1.4× 80 0.4× 164 1.0× 12 562

Countries citing papers authored by Eva Hambruch

Since Specialization
Citations

This map shows the geographic impact of Eva Hambruch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Hambruch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Hambruch more than expected).

Fields of papers citing papers by Eva Hambruch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Hambruch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Hambruch. The network helps show where Eva Hambruch may publish in the future.

Co-authorship network of co-authors of Eva Hambruch

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Hambruch. A scholar is included among the top collaborators of Eva Hambruch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Hambruch. Eva Hambruch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Hollenback, David, Eva Hambruch, Andreas Schulz, et al.. (2024). Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease. Journal of Pharmacology and Experimental Therapeutics. 389(1). 61–75. 3 indexed citations
2.
Gopalswamy, Mohanraj, Zheng Chen, Hamed Kooshapur, et al.. (2022). Distinct conformational and energetic features define the specific recognition of (di)aromatic peptide motifs by PEX14. Biological Chemistry. 404(2-3). 179–194. 3 indexed citations
3.
Schwabl, Philipp, Eva Hambruch, Grant R. Budas, et al.. (2021). The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. Biomedicines. 9(1). 60–60. 49 indexed citations
4.
Gege, Christian, Eva Hambruch, Nina Hambruch, Olaf Kinzel, & Claus Kremoser. (2019). Nonsteroidal FXR Ligands: Current Status and Clinical Applications. Handbook of experimental pharmacology. 256. 167–205. 67 indexed citations
5.
Hambruch, Eva, David Hollenback, Olaf Kinzel, et al.. (2019). FRI-303-How to develop a differentiated FXR agonist: GS-9674 shows a reduced side effect profile in mice, monkeys amd human phase 1 studies compared to its predecessor Px-102. Journal of Hepatology. 70(1). e528–e529. 2 indexed citations
6.
Schwabl, Philipp, Grant R. Budas, Eva Hambruch, et al.. (2018). The FXR agonist GS-9674 reduces fibrosis and portal hypertension in a rat model of NASH. Journal of Hepatology. 68. S471–S472. 3 indexed citations
7.
Schwabl, Philipp, Eva Hambruch, Hubert Hayden, et al.. (2016). The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. Journal of Hepatology. 66(4). 724–733. 137 indexed citations
8.
Kinzel, Olaf, Christoph Steeneck, Thomas Schlüter, et al.. (2016). Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties. Bioorganic & Medicinal Chemistry Letters. 26(15). 3746–3753. 27 indexed citations
9.
Schwabl, Philipp, Eva Hambruch, Michael Burnet, et al.. (2016). The Non-Steroidal Fxr Agonist Gs-9674 Reduces Liver Fibrosis and Ameliorates Portal Hypertension in a Rat Nash Model. Journal of Hepatology. 64(2). S165–S166. 8 indexed citations
10.
Hambruch, Eva, Olaf Kinzel, & Claus Kremoser. (2016). On the Pharmacology of Farnesoid X Receptor Agonists: Give me an “A”, Like in “Acid”. SHILAP Revista de lepidopterología. 3. 2 indexed citations
11.
Karnik, Satyajit, Eva Hambruch, Claus Kremoser, et al.. (2016). Fxr Agonism by Gs-9674 Decreases Steatosis and Fibrosis in a Murine Model of Nash. Journal of Hepatology. 64(2). S169–S169. 19 indexed citations
12.
Schwabl, Philipp, Eva Hambruch, B.A. Payer, et al.. (2015). G18 : The FXR agonist PX20606 reduces liver damage, fibrosis and portal hypertension in cirrhotic rats. Journal of Hepatology. 62. S238–S238. 2 indexed citations
13.
Neuhaus, Alexander, Hamed Kooshapur, Janina Wolf, et al.. (2014). A Novel Pex14 Protein-interacting Site of Human Pex5 Is Critical for Matrix Protein Import into Peroxisomes. Journal of Biological Chemistry. 289(1). 437–448. 48 indexed citations
14.
Deuschle, Ulrich, Eva Hambruch, Martin Hornberger, et al.. (2014). The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidine‐rich glycoprotein. International Journal of Cancer. 136(11). 2693–2704. 15 indexed citations
15.
16.
Kremoser, Claus, Eva Hambruch, Ulrich Deuschle, et al.. (2011). 99 NOVEL FXR AGONISTS WITH POTENT LIPID LOWERING, INSULIN SENSITISING, ANTI-INFLAMMATORY AND ANTI-FIBROTISATION EFFECTS IN MOUSE MODELS OF METABOLIC SYNDROME AND NASH. Journal of Hepatology. 54. S44–S44. 3 indexed citations
17.
Abel, Ulrich, Thomas Schlüter, Andreas Schulz, et al.. (2010). Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. Bioorganic & Medicinal Chemistry Letters. 20(16). 4911–4917. 47 indexed citations
18.
Hambruch, Eva, Harald W. Platta, Ben de Kruijff, et al.. (2006). Membrane Association of the Cycling Peroxisome Import Receptor Pex5p. Journal of Biological Chemistry. 281(37). 27003–27015. 91 indexed citations
19.
Costa‐Rodrigues, João, Andreia F. Carvalho, Marc Fransen, et al.. (2005). Pex5p, the Peroxisomal Cycling Receptor, Is a Monomeric Non-globular Protein. Journal of Biological Chemistry. 280(26). 24404–24411. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cristina Di Giorgio Breakdown of academic impact, for papers by Michaela Mueller Breakdown of academic impact, for papers by Justin D. Schumacher Breakdown of academic impact, for papers by Dina Hazem Ziada Breakdown of academic impact, for papers by Vittoria Massafra Breakdown of academic impact, for papers by Florence Y. Lee Breakdown of academic impact, for papers by Kangkang Yu Breakdown of academic impact, for papers by Asato Tachibana Breakdown of academic impact, for papers by Mariska Geuken Breakdown of academic impact, for papers by Yi-Ping Rao
Rankless by CCL
2026